Last reviewed · How we verify
Prednisone therapy and pharmacokinetic
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Prednisone is a corticosteroid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis), Allergic reactions and asthma exacerbations, Adrenal insufficiency.
At a glance
| Generic name | Prednisone therapy and pharmacokinetic |
|---|---|
| Sponsor | University Hospital, Caen |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology, Rheumatology, Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Prednisone acts as a glucocorticoid receptor agonist, translocating to the nucleus to modulate gene expression of inflammatory mediators. It decreases production of cytokines (IL-1, IL-6, TNF-α), reduces immune cell activation and proliferation, and stabilizes lysosomal membranes to prevent release of inflammatory enzymes. These effects make it effective across multiple inflammatory and autoimmune conditions.
Approved indications
- Inflammatory and autoimmune disorders (rheumatoid arthritis, lupus, vasculitis)
- Allergic reactions and asthma exacerbations
- Adrenal insufficiency
- Certain hematologic malignancies and lymphomas
- Organ transplant rejection prophylaxis
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes (anxiety, irritability)
- Osteoporosis (chronic use)
- Immunosuppression/increased infection risk
- Gastrointestinal upset
- Weight gain
Key clinical trials
- Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (PHASE3)
- Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma (PHASE2)
- A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients (PHASE2)
- PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients (PHASE1)
- Renal Transplantation in the Elderly - nEverOld Study (PHASE4)
- Steroids Pharmacokinetics and the Response to Prednisone Therapy in Giant Cell Arteritis (PHASE4)
- Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |